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Summary
Obesity, metabolic syndrome, and hyperleptinemia are associ-
ated with aging and age-associated diseases including prostate
cancer. One experimental approach to inhibit tumor growth is to
reduce dietary protein intake and hence levels of circulating
amino acids. Dietary protein restriction (PR) increases insulin
sensitivity and suppresses prostate cancer cell tumor growth in
animal models, providing a rationale for clinical trials. We sought
to demonstrate that biomarkers derived from plasma extracellu-
lar vesicles (EVs) reflect systemic leptin and insulin signaling and
respond to dietary interventions. We studied plasma samples
from men with prostate cancer awaiting prostatectomy who
participated in a randomized trial of one month of PR or control
diet. We found increased levels of leptin receptor in the PR group
in total plasma EVs and in a subpopulation of plasma EVs
expressing the neuronal marker L1CAM. Protein restriction also
shifted the phosphorylation status of the insulin receptor signal
transducer protein IRS1 in L1CAM+ EVs in a manner suggestive of
improved insulin sensitivity. Dietary PR modifies indicators of
leptin and insulin signaling in circulating EVs. These findings are
consistent with improved insulin and leptin sensitivity in
response to PR and open a new window for following physio-
logic responses to dietary interventions in humans.
Key words: exosomes; extracellular vesicles; IRS-1; leptin
receptor; prostate cancer; protein restriction.
Obesity and insulin resistance are associated with accelerated aging and
increased risk of many age-related diseases (Mattson et al., 2016). The
risk of many cancers, including prostate cancer, increases with age and
being overweight further increases this risk (Longo & Fontana, 2010;
Neuhouser et al., 2015). A protein restriction (PR) diet was shown to
reduce weight and improve metabolic health in both animal models and
humans, and researchers have started to elucidate beneficial effects of
dietary PR in cancer patients (Fontana et al., 2013, 2016; Kopeina et al.,
2017). The mechanism by which PR diet improves metabolism and slows
down cancer progression is not yet fully understood. One reasonable
hypothesis is that PR modulates the levels of adipokines and other
endocrine signals that affect cancer progression. For instance, elevated
blood concentration of FGF21 and adiponectin and reduced levels of
leptin were previously observed in humans and animal models in
response to PR diet (Johnson et al., 2007; Harvie et al., 2013; Fontana
et al., 2016).
In the current study, we are investigating the effect of PR diet on
molecular mediators in Extracellular vesicles (EV). EVs are small membra-
nous particles that serve in intercellular communication by delivering
proteins, RNA, DNA, and bioactive lipids (Yanez-Mo et al., 2015). We
postulate that EV-bound molecules reflect cellular and metabolic pro-
cesses in their cells of origin, whichmay bemodulated by PR diet and serve
as biomarkers for following personalized diet responses. Here, we used a
two-step method (first precipitating total EVs, then, immunoprecipitating
EVs that express L1CAM to generate a subpopulation enriched for
neuronal origin) (Kapogiannis et al., 2015; Mustapic et al., 2017) to
isolate EVs from plasma samples (1 ml) of 38 subjects at baseline and
following 1 month of dieting. Subjects were men with prostate cancer
awaiting prostatectomy surgery, most of whom were overweight
(BMI = 30.45  5.8; Age = 59.26  7.5 years), that were randomly
assigned to either a control diet or a PR diet. The PR diet was individualized
so that each patient received 0.8 g protein kg1 lean body mass;
consequently, PR meals were provided by the investigators, while the
control group maintained their regular diet. This difference in handling
subjects was dictated by practical considerations andmight be considered
as a confounding factor. For further description of the study design,
macronutrient breakdown and subjects baseline characteristics see
(Fontana et al., 2016), (Fig. S1; Table S1; Appendix S1). The quality of
the EV preparations was evaluated by nanoparticle tracking analysis and
Western blots for EVmarkers ALIX andCD9 (Fig. 1). The isolated EVs had a
typical diameter size distribution, with the majority having diameters
between 100 and 180 nm (Fig. 1A). The EV preparations showed
expression of canonical EV markers ALIX and CD9 (Fig. 1B). There were
no significant changes in EV size distributions from baseline to after
1 month of either diet (interaction of diet type and time point, F(1,
36) = 0.101, P = 0.753) (Fig. 1A). EV concentration was included as a
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covariate in all subsequent analyses to control for differential EV content
between samples.
After establishing that EV concentration is not changing in response
to the PR diet, we shifted our attention to their content, focusing on
leptin receptor (LeR) and the insulin signaling protein IRS1. While levels
of leptin and insulin have been extensively measured in plasma samples
of obese and aged individuals (Gumbiner et al., 1989; Balasko et al.,
2014), their receptors and downstream signaling mediators are not
being routinely measured in human studies. The isolation of EVs opens
the opportunity to measure these nonhormonal protein mediators and
hopefully assess cellular responses to the diets in living humans.
Moreover, while measuring levels of soluble factors in plasma only gives
indications of systemic changes, plasma EVs can be sorted based on their
surface proteins to study cell-origin specific populations. We published
several studies on plasma-derived neuronal-enriched EVs and their
potential to open a window into phenotypic changes of the human brain
(Kapogiannis et al., 2015; Mustapic et al., 2017). The plasma-derived
neuronal-enriched EVs are selected based on the presence of the
neuronal marker L1CAM on their surface. We previously demonstrated
that they represent a distinct subpopulation that is enriched for several
neuronal proteins and interestingly also contain elevated levels of
hormone receptors and intracellular signaling molecules like mTOR, IRS1,
and leptinR (Mustapic et al., 2017) compared to total EVs, perhaps, a
reflection of the high neuronal metabolic activity. Leptin is released from
adipocytes and activates receptors on neurons in the brain that enhance
satiety, thereby inhibiting excessive food intake (Park & Ahima, 2015).
Obese humans typically experience a heightened sense of hunger
despite elevated leptin levels, perhaps due to the development of leptin
resistance (Gautron & Elmquist, 2011). The concentration of leptin in
blood is elevated in obese individuals and is inversely correlated with age
(Balasko et al., 2014). Here, we measured the levels of EV-associated LeR
and showed that the PR diet produced a significant increase from
baseline and in comparison with the control diet (interaction of diet type
and time point, F(1, 36) = 6.52, P = 0.015; univariate post hoc
comparison of the two diets after 1 month, F(1, 43) = 5.579,
P = 0.021; univariate post hoc comparison between baseline and
1 month after PR diet, F(1, 36) = 9.311, P = 0.004) (Fig. 2A). The PR
diet produced an even greater and highly significant LeR increase from
baseline and compared to the control diet in neuronal-enriched EVs
(interaction of diet type and time point, F(1, 36) = 20.120, P < 0.001;
univariate post hoc comparison of the two diets after 1 month, F(1,
43) = 6.41, P = 0.015; univariate post hoc comparison between base-
line and 1 month after PR diet, F(1, 35) = 52.772, P < 0.001) (Fig. 2B).
In other words, 1 month of PR increased LeR levels in total and neuronal-
enriched EVs, unlike the control diet.
Insulin is an important regulator of metabolism, and proper insulin
signaling is critical for cellular health. Reduction in insulin sensitivity is the
Fig. 1 Characterization of EV populations and results of ELISA analysis of a select
group of energy metabolism-related proteins in L1CAM+ EVs. (A) The size
distribution of L1CAM EVs from 19 control and 19 PR diet subjects at baseline and
after 1 month of dietary intervention was measured by NTA. (B) Immunoblot
analysis for the EV markers ALIX and CD9 in nine randomly chosen samples of
isolated L1CAM EVs.
Fig. 2 Levels of leptin receptor and the pY/pSer312 IRS1 ratio in EVs. (A) Levels of leptin receptor after a month of PR diet were significantly higher than baseline levels and
control levels in total EVs. (B) Levels of leptin receptor after a month of PR diet were significantly higher than baseline levels and control levels in L1CAM+ EVs. (C) The ratio
between pan-tyrosine and serine 312 phosphorylated IRS1 in L1CAM+ EVs. Bars depict means, and error bars depict SEM; * indicates significance < 0.05; ** indicates
significance < 0.01; and *** indicates significance < 0.001.
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underlying cause of type 2 diabetes and a characteristic of obesity and
unhealthy aging (Bartke, 2008). IRS1 is an adapter protein that mediates
the downstream signaling of insulin and insulin-like growth factor
receptors. Phosphorylation of IRS1 on tyrosine residues increases its
activity while phosphorylation on serine 312 decreases its activity (Copps
& White, 2012). The ratio of pan-tyrosine (pY) to serine 312 phospho-
rylated (pSer312) IRS1 (Y/S IRS1 ratio) was shown to decrease in response
to insulin resistance in cell studies (Copps & White, 2012), and we have
recently shown that it is significantly decreased in neuronal-enriched EVs
of patients with Alzheimer’s disease (AD) compared to controls
(Kapogiannis et al., 2015), in whom it is also associated with regional
atrophy (Mullins et al., 2017). The PR diet was previously reported to
increase insulin sensitivity in these subjects (measured by HOMA-IR)
(Fontana et al., 2016), and therefore, we were interested to test whether
it also changes the Y/S IRS1 ratio in neuronal-enriched EVs, which would
further validate its use as a biomarker reflecting neuronal insulin
sensitivity. After 1 month of PR diet, subjects had higher Y/S IRS1 ratio
in neuronal-enriched EVs compared to subjects on control diet (interac-
tion of diet type and time point, F(1, 35) = 1.259, P = 0.269; univariate
post hoc comparison between PR diet and control diet after 1 month, F(1,
67) = 8.889, P = 0.004). This difference indicates a more active insulin
signaling pathway after PR diet compared to control diet (Fig. 2C). To
assess whether baseline BMI affects LeR and Y/S IRS1 ratio results, we
explored models, in which baseline BMI was included as covariate, as well
as the triple interaction term ‘timepoint*treatment*BMIbaseline’. Neither
BMI nor the interaction term reached significance; therefore, we report
simpler models without covarying baseline BMI.
The results of the current study further show that circulating EVs
can serve as a source of biomarkers for cellular metabolism. PR diet,
which was previously reported to significantly reduce BMI, increase
insulin sensitivity and FGF21 concentration and produce a trend
toward reduced prostate-specific antigen (PSA) levels in urine (Fontana
et al., 2016), also increased the levels of EV-associated LeR and Y/S
IRS1 ratio. There are two major advantages of EV-based biomarkers.
First, EV content is directly derived from the intracellular compartment
and their levels of cellular mediators like IRS1 and LeR may better
represent cellular metabolic status than circulating soluble mediators.
In this regard, it will be interesting to measure additional metabolism-
related proteins, such as mTOR, which we have recently shown to be
present in EVs (Mustapic et al., 2017), in its native and phosphory-
lated active forms, as it is known to regulate IRS1 phosphorylation
(Chiarini et al., 2015). Second, EVs express cell specific proteins on
their surface (Yanez-Mo et al., 2015), which can be used as a handle
to enrich for EVs originating from specific cell types (Mustapic et al.,
2017), potentially allowing conclusions to be drawn about diet effects
on specific cell types. Further animal studies are needed to establish
the association between the levels of these biomarkers in circulating
EVs and in their cells of origin to determine whether they provide an
accurate insight into the molecular alterations occurring in different
tissues. In particular, insulin resistance of specific cell types is significant
for several age-related diseases. In this regard, we have found reduced Y/
S IRS1 ratio in AD patients, which likely corresponds to increased insulin
resistance, particularly affecting brain regions suffering from AD pathol-
ogy (Talbot et al., 2012; Kapogiannis et al., 2015; Mullins et al., 2017).
Our present results show that PR diet increases the Y/S IRS1 ratio in
neuronal-enriched EVs, which suggests that this diet may improve insulin
sensitivity in neurons. These results suggest an explanation for the vast
body of findings in animal studies indicating that PR and calorie restriction
can counteract several major age-related diseases (Mattson et al., 2016;
Simpson et al., 2017). The reduction in sensitivity to insulin, leptin, and
probably other hormones and trophic factors with age is probably one of
the drivers of aging and an underlying cause of age-related diseases. The
ability to monitor this process in humans longitudinally by a minimally
invasive intervention such as a blood draw is of great value for
understanding mechanisms of aging, for monitoring age-related disease
processes and for assessing responses of systemic and tissue-specific
metabolism to therapeutic interventions including diet, exercise, lifestyle
modifications and drugs (Longo et al., 2015). We believe that EVs offer a
unique ‘window’ into these processes and that the current study provides
a proof of concept for their use as a source of biomarkers for age-related
metabolism alterations.
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